Hide metadata

Health economic evaluation of Ramucirumab plus Docetaxel in second-line treatment for stage IV non-small lung cancer. A cost-utility analysis in a Norwegian setting.

dc.contributor.authorRistun, Cilia Schulstad
dc.date.accessioned2017-02-22T22:27:33Z
dc.date.issued2016
dc.identifier.citationRistun, Cilia Schulstad. Health economic evaluation of Ramucirumab plus Docetaxel in second-line treatment for stage IV non-small lung cancer. A cost-utility analysis in a Norwegian setting.. Master thesis, University of Oslo, 2016
dc.identifier.urihttp://hdl.handle.net/10852/53975
dc.description.abstracteng
dc.language.isoeng
dc.subject
dc.titleHealth economic evaluation of Ramucirumab plus Docetaxel in second-line treatment for stage IV non-small lung cancer. A cost-utility analysis in a Norwegian setting.eng
dc.typeMaster thesis
dc.date.updated2017-02-22T22:27:33Z
dc.creator.authorRistun, Cilia Schulstad
dc.date.embargoenddate3016-06-20
dc.rights.termsDette dokumentet er ikke elektronisk tilgjengelig etter ønske fra forfatter. Tilgangskode/Access code A
dc.identifier.urnURN:NBN:no-57110
dc.type.documentMasteroppgave
dc.rights.accessrightsclosedaccess
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/53975/1/CiliaSchulstadRistun.pdf


Files in this item

Name:
CiliaSchulstadRistun.pdf
Size:
1.339Mb
Format:
application/
View/Open

Appears in the following Collection

Hide metadata